Listed

Benitec Biopharma Inc.: Form 10-Q for the period ended Sep 30, 2021

Filed with the SEC on Nov 15, 2021 and accepted by EDGAR at Nov 15, 2021, 06:10 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2021-07-01 to 2021-09-30$0us-gaap:Revenues
Research and development3 months2021-07-01 to 2021-09-30$2.8mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2021-07-01 to 2021-09-30−$4.8mus-gaap:OperatingIncomeLoss
Net income3 months2021-07-01 to 2021-09-30−$5.0mus-gaap:NetIncomeLoss
Operating cash flow3 months2021-07-01 to 2021-09-30−$4.3mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2021-07-01 to 2021-09-30$0us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2021-09-30$15.7mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-09-30$16.4mus-gaap:AssetsCurrent
Total assetsAt period end2021-09-30$17.8mus-gaap:Assets
Current liabilitiesAt period end2021-09-30$1.6mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-09-30$2.4mus-gaap:Liabilities
Shareholders' equityAt period end2021-09-30$15.5mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001193125-21-328795. Last ingested by Listed: Nov 14, 2026, 11:28 ET. Listed shows no prices and gives no investment advice.